SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report

05/19/2022 | 01:31pm EDT

Gilead Sciences, Inc. (Nasdaq: GILD) today was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report released by Funders Concerned About AIDS (FCAA). The report, found at:, is released annually and is widely regarded as the most comprehensive study of its kind. It analyzes 2020 funding data (the most recent year available) revealing that Gilead’s philanthropic support wholly drove the increase of private HIV and AIDS philanthropic funding – representing 38% of all HIV funding and driving a majority of the increases in funding across all issues, populations and geographies. Gilead is also recognized in the report as the number one funder in the U.S. and the number three funder internationally. The report indicates that, “Private HIV and AIDS philanthropic funding to the U.S. rose for the seventh year in a row, totaling over $321 million in 2020, a dramatic 52% ($109 million) increase from 2019.”

In addition to being recognized as the number one funder both overall and in the U.S., Gilead was also recognized as the number one funder across a range of categories, including:

  • Number one funder addressing the COVID-19 pandemic
  • Number one funder of Black, Indigenous and people of color communities in the U.S.
  • Number one corporate funder

“Gilead's support for community organizations is part of our enduring commitment to ending the HIV epidemic,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “We believe that real progress is only possible through collaboration and partnership. That is why we invest in the extraordinary efforts our partners are undertaking to reach underserved populations, eliminate barriers to care and educate communities. It is inspiring to see the work that goes on across these groups and we are proud to play a role in supporting them.”

Gilead’s philanthropic efforts are administered through a number of signature initiatives and programs designed to reach key populations and communities across the U.S. and around the world.

RADIAN®, launched in 2019 with the Elton John AIDS Foundation, addresses challenges in Eastern Europe and Central Asia, where the annual rate of HIV diagnoses continues to rise. In the U.S., HIV Age Positively® aims to improve the health and quality of life for those who are aging and TRANScend® supports Trans-led organizations improving the safety, health and wellness of the Transgender community.

To assist grantees who faced imminent closure or termination of services as a result of the COVID-19 pandemic, Gilead CARES was launched in 2020, providing up to $20 million in donations to nonprofit groups. The Gilead COMPASS Initiative®, a 10-year, $100+ million partnership with community-based organizations, is working to combat the HIV epidemic in the Southern United States, and is responsible for driving sharp increases in funding across the U.S. South, which had been in decline over the previous two years.

According to the report, “In 2020, funding disbursements to the U.S. South increased sharply, by $28 million (76%), after having declined the two previous years. Again, as in 2017, this increase is largely attributed to large disbursements for Gilead’s COMPASS Initiative. COMPASS funding is distributed to its coordinating centers, located across the U.S. South, in large sums, but is then granted out into the community over a couple of years.”

More information about Gilead’s signature funding initiatives and programs can be found at:

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Today, millions of people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.

For more information about Gilead, please visit the company’s website at, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

© Business Wire 2022
All news about GILEAD SCIENCES, INC.
07/01GlaxoSmithKline plc completed the acquisition of Sierra Oncology, Inc. from Frazier Hea..
06/29Kite's CAR T-cell Therapy Yescarta Granted European Marketing Authorization for the Tre..
06/28Kite's CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Tr..
06/27Gilead Sciences Resubmits Application for HIV Treatment Candidate
06/27Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapa..
06/27Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapa..
06/27Gilead Sciences, Inc. - Investigational Lenacapavir Receives Positive CHMP Opinion for ..
06/27Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Negle..
06/24Gilead Sciences Receives Positive CHMP Opinion for HIV Drug
06/24Gilead Sciences, Inc. - Treatment With Hepcludex (Bulevirtide) Meets Primary Endpoint a..
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 24 543 M - -
Net income 2022 4 227 M - -
Net Debt 2022 16 327 M - -
P/E ratio 2022 17,7x
Yield 2022 4,66%
Capitalization 78 219 M 78 219 M -
EV / Sales 2022 3,85x
EV / Sales 2023 3,78x
Nbr of Employees 14 400
Free-Float 99,9%
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 62,36 $
Average target price 69,65 $
Spread / Average Target 11,7%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-14.12%78 219
WUXI APPTEC CO., LTD.-7.99%44 566
BIONTECH SE-38.91%38 276
GENMAB A/S-10.23%21 607